Coherus Oncology (CHRS) Debt to Equity (2014 - 2026)

Coherus Oncology has disclosed Debt to Equity across 13 years of filings, most recently posting $0.47 for Q1 2026.

• Debt to Equity for Q1 2026 came in at $0.47, up 237.57% year-over-year; the trailing twelve-month figure through Mar 2026 was $0.47 (up 237.57% YoY), and the FY2025 annual result was $0.61, up 259.29% from the prior year.
• Debt to Equity came in at $0.47 for Q1 2026 at Coherus Oncology, down from $0.61 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $15.59 in Q1 2022 to a low of -$8.66 in Q2 2022.
• The 5-year median for Debt to Equity is -$0.54 (2024), against an average of -$0.24.
• Peak annual rise in Debt to Equity reached 2564.54% in 2022, while the deepest fall reached 1905.47% in 2022.
• Coherus Oncology's Debt to Equity stood at -$1.79 in 2022, then gained by 27.71% to -$1.29 in 2023, then surged by 70.48% to -$0.38 in 2024, then soared by 259.29% to $0.61 in 2025, then dropped by 22.2% to $0.47 in 2026.
• The last three Debt to Equity figures came in at $0.47 (Q1 2026), $0.61 (Q4 2025), and $0.42 (Q3 2025), per Business Quant data.